CAU
ANIP icon

Caxton Associates (UK)’s ANI Pharmaceuticals ANIP Stock Holding History

Caxton Associates (UK)’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-37,848
Closed -$2.99M – 773
2025
Q4 		$2.99M Hold
37,848
– – 0.06% 123
2025
Q3 		$3.47M Buy
+37,848
New +$3.09M 0.08% 108

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Caxton Associates (UK)'s ANIP Position: Q1 2026 in Review

Caxton Associates (UK) sold out of ANI Pharmaceuticals (ANIP) in Q1 2026, closing a stake of 37,848 shares — an estimated $2.99M sold.

Caxton Associates (UK) first reported a position in ANIP in Q3 2025 and held it in 2 quarters. The position peaked at $3.47M in Q3 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Caxton Associates (UK) reported no remaining ANI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 37,848 ANI Pharmaceuticals shares in Q1 2026, an estimated $2.99M.
  • Caxton Associates (UK) first reported a position in ANI Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Caxton Associates (UK)'s ANI Pharmaceuticals position peaked at $3.47M in Q3 2025.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.